34 results about "Cell adhesion molecule" patented technology

Provided is a novel anti-CADM1 antibody or an antigen-binding fragment thereof. An anti-CADM1 antibody or antigen-binding fragment thereof according to the present disclosure binds to an epitope comprising amino acid residues at positions 311, 325 and 326 in cell adhesion molecule 1 (CADM1).

The invention provides an application of a carcino-embryonic antigen related cell adhesion molecule 5 (CEACAM5) in treatment of pancreatic cancer. Research finds that a novel stem cell-like cluster cell subtype (hereinafter referred to as' stem cell-like TCs') is found, and the subtype is significantly related to poor prognosis of pancreatic ductal adenocarcinoma patients. Therefore, the invention provides a novel pancreatic ductal adenocarcinoma treatment medicine, namely the carcino-embryonic antigen related cell adhesion molecule 5, which has very positive significance on the treatment of the pancreatic ductal adenocarcinoma.

Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and / or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK / PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.

A modified cell is provided that expresses (a) a chimeric antigen receptor targeting GPC3 and / or CD19, and (b) a multispecific antigen binding protein, variant or binding fragment thereof that binds to one or more targets, comprising a first antigen binding protein, variant or binding fragment thereof that binds to EpCAM (epithelial cell adhesion molecule), and a second antigen binding protein, variant or binding fragment thereof, which binds to an immune cell marker, wherein the first antigen binding protein, variant or binding fragment thereof, which binds to EpCAM comprises a heavy chain variable region and / or a light chain variable region comprising a sequence as disclosed herein. Also disclosed are methods of generating / generating cells as disclosed herein and methods of treating with cells as disclosed herein.

Peptides, proteins, antibodies, antibody fragments, or antigen-binding fragments thereof, against cell adhesion molecules for use as immunotherapeutics.

Disclosed are compositions including a population of human enteric neural stem cells (ENSCs), wherein the population comprises at least one of a cell expressing nerve growth factor receptor (NGFR), a cell expressing integrin alpha 6 (ITGA6), a cell expressing L1 cell adhesion molecule (L1CAM), a cell that expresses proteolipid protein 1 (PLP1), and / or a cell that expresses paired-like homeobox 2B (PHOX2B), methods of producing the compositions, and their uses.

Disclosed herein are immune cell engagers. The immune cell engager may include a cell binding domain, an immune cell adhesion molecule, an immune cell costimulatory molecule, or a combination thereof. Methods of use and production are further provided.

Pharmaceutical compositions containing anti-CEACAM 1 mAbs and their use in inhibiting NET-mediated activities and in the prevention and treatment of conditions associated with these activities are provided, exemplified by mAb CM24, which has also been shown to effectively inhibit cancer cell migration and NET-induced platelet aggregation. Additionally, prognostic methods based on NET biomarkers for use in patient selection and monitoring treatment efficacy are presented.

It is provided a method for analyzing an isolated airway secretion sample of an equine patient in vitro, the method comprising the following steps: a) providing an isolated airway secretion sample originating from an equine patient, b) determining the concentration of at least one protein chosen from the group consisting of mucin-4, polymeric immunoglobulin receptor, carcinoembryonic antigen-related cell adhesion molecule 1, CD177, and vanin 1 in the isolated airway secretion sample, c) determining that the equine patent suffers from equine asthma if the concentration of the at least one protein exceeds a predeterminable threshold.

Methods of using pulsed focused ultrasound (pFUS) therapy to treat pancreatic disorders such as type 1 diabetes, pancreatitis, and pancreatic cancer are provided. The methods utilize pulsed focused ultrasound (pFUS) therapy either by itself or in combination with islet transplantation and / or stem cell therapy to promote regeneration of damaged pancreatic tissue, increase insulin secretion in response to glucose, or improve engraftment and revascularization of transplanted islets or beta cells. Additionally, methods of using pFUS are provided for modulating paracrine secretion in the pancreas, islets, beta cells, or stem cells, or at a transplantation site to therapeutically alter levels of various factors including, without limitation, cytokines, growth factors, angiogenic factors, and cell adhesion molecules.

The application belongs to the technical field of micro-robot preparation, and provides a magnetic micro-robot with ROS response and shape self-adaptability, a preparation method and application thereof. The preparation method comprises the following steps: mixing eight-arm polyethylene diamine, eight-arm succinimidyl carboxylate, iron oxide nanoparticles, antioxidant material, cell adhesion molecule and PBS buffer to obtain a mixture; mixing the mixture with n-hexane, liquid paraffin and span 80, and performing magnetic stirring, and then standing to obtain a magnetic micro-robot mixture; and separating the magnetic micro-robot mixture by using a permanent magnet to obtain magnetic gel microspheres, i.e. the magnetic micro-robot. The magnetic micro-robot prepared by the application has ROS response and good shape self-adaptability, and can be widely applied to the medical field.

The invention belongs to the technical field of medicines, and discloses application of berberine serving as an active ingredient of rhizoma coptidis to preparation of a medicine for preventing and / or treating vascular injury. According to the application disclosed by the invention, an action target of berberine serving as a core component of coptis chinensis is predicted through network pharmacology, and then a tumor necrosis factor-alpha stimulated human umbilical vein endothelial cell (HUVEC) model is used for verification; it is proved that berberine down-regulates the expression of downstream key inflammatory factors (IL-6 and IL-8), monocyte chemotactic protein-1 (MCP-1), cell adhesion molecule vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1). Based on this, the invention provides a candidate drug with novel mechanism and multi-target effect for prevention and treatment of atherosclerosis, and has important development value and application prospect.

The invention discloses a culture method for inducing human cerebral cortex organoid differentiation through cell adhesion molecules, and belongs to the technical field of organoid culture. The culture method comprises the following steps: culturing stem cells by using an mTeSR culture solution, screening, decomposing into single cells, centrifugally precipitating, re-suspending in an organoid differentiation culture solution I, inoculating, culturing to the 18th day, transferring an organoid into a low-adhesion culture dish, replacing the culture solution with an organoid differentiation culture solution II, and culturing from the 18th day to the 35th day; replacing the culture solution with an organoid differentiation culture solution III, and culturing from the 35th day to the 70th day; and finally, replacing the culture solution with an organoid differentiation culture solution IV, and culturing after 70th day. The culture method provided by the invention optimizes the culture of cerebral cortex organs, has repeatability, does not interfere with a key signal channel and does not deviate from a physiological development mechanism, and can be widely and accurately used for disease modeling.

The application discloses application of ferritin-carrying neuron-derived extracellular vesicles in auxiliary diagnosis of Parkinson's disease and belongs to the field of biomedical technology. The application realizes effective identification of specific ferritin-carrying neuron-derived extracellular vesicles in a flow cytometer by fluorescence labeling of L1 cell adhesion molecule antibodies and ferritin heavy chain antibodies, and can accurately distinguish PD patients, MSA patients and healthy people by analyzing the concentration of the ferritin-carrying neuron-derived extracellular vesicles in blood plasma, thereby providing an efficient PD diagnosis biomarker and greatly improving the ability of early diagnosis of PD and identification of MSA and PD, and effectively solving the problems of complexity and low sensitivity faced by traditional diagnosis methods.

The present disclosure relates to methods for generating progenitors functionally totipotent blastomere-like stem cells via P ARP -regulated proteomic reprogramming of a PARP- DUX4-NAN0G regulatory axis of conventional human induced pluripotent stem cells (hiPSC) by chemically reverting them to tankyrase / PARP1 inhibitor-regulated naive (TIRN) human stem cells and methods and compositions useful for generating chimeras using such human induced totipotent TIRN stem cells. In certain embodiments, the TIRN stem cells are engineered to express a cell adhesion molecule (e.g., E-Cadherin) or DUX4.

The invention belongs to the technical field of biomedical engineering and cell therapy, and particularly relates to a preparation method of a mesenchymal stem cell exosome capable of improving an anti-inflammatory function. The core is a collaborative design of composite biochemical pre-stimulation and inflammatory microenvironment response type three-function targeting anchoring. A tumor necrosis factor-alpha with a concentration of 5-8 ng / mL, a resveratrol derivative with a concentration of 2-5 [mu] mol / L and glutathione with a concentration of 10-20 [mu] mol / L are adopted for reverse synergistic pre-stimulation, such that an anti-inflammatory pathway is activated; a vascular cell adhesion molecule-1 targeting domain-matrix metalloproteinase-9 sensitive connecting arm-LL-37 anti-inflammatory domain fusion polypeptide is anchored, so that precise targeting and response release are realized. According to the method, the problems of insufficient anti-inflammatory activity, poor targeting and off-target of the exosome are solved, the enrichment amount of an inflammatory site is increased by 2.5-4 times, the TNF-alpha inhibition rate reaches 90%-95%, and the exosome is suitable for treating inflammatory diseases.

The invention discloses a thalassemia treatment method based on a stem cell technology and application. The thalassemia treatment method comprises the following steps: collecting a peripheral blood sample of a patient, and carrying out stem cell isolated culture; constructing a nucleic acid aptamer by combining a vascular cell adhesion molecule-1 and a stromal cell-derived factor-1 in a bone marrow microenvironment; connecting a nucleic acid aptamer, a cell adhesion promoting peptide and a stem cell growth factor, and constructing a homing guiding reagent; preparing nano liposome and nano polymer particles; the nucleic acid aptamer is connected to the surfaces of the nano-liposome and the nano-polymer particles, and is grafted with a temperature-responsive material to obtain the nano-carrier with a responsive release function; stem cell growth factors and platelet-derived growth factors are mixed with gelatin microspheres to form a slow release system; the cultured stem cells are mixed with a homing guide reagent, a nano-carrier and a slow release system, and are transplanted into the body of a patient through intramedullary injection. The stem cell homing efficiency can be improved, and the treatment effect on thalassemia is improved.

The invention belongs to the technical field of plasma protein markers, and discloses a plasma protein marker and a risk prediction system for a heart failure onset risk of a type 2 diabetes mellitus patient, and the protein marker combination is applied to preparation of a kit for predicting the heart failure onset risk of the type 2 diabetes mellitus patient. The protein marker combination comprises a C-C motif chemotactic factor 24, a C-C motif chemotactic factor 7, a carcino-embryonic antigen related cell adhesion molecule 6, a fiber gelling protein 1, a follistatin, a polypeptide N-acetylgalactosamino transferase 5, an ADP ribosylation factor binding protein GGA1, a kallikrein 4, a nerve bundle protein, renin, a plasma protease C1 inhibitor and cardiac troponin I, the brain natriuretic peptide comprises a brain natriuretic peptide precursor, an N-terminal brain natriuretic peptide precursor, apolipoprotein C1, tetramer connexin, a Mepin A beta subunit and multi-ligand proteoglycan-4. The invention further constructs a risk score and prediction model for predicting the attack risk of the heart failure of the type 2 diabetes mellitus patient based on the protein marker.

Provided are stabilized formulations of the human carcinoembryonic antigen-related cell adhesion molecule 5 (hCEACAM5)-targeted antibody-drug conjugate huMAb2-3-SPDB-DM4, as well as methods for making and using same.30

Provided herein are recombinant antibodies and antigen-binding fragments thereof useful for binding to and inhibiting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). Also provided are methods of using the disclosed CEACAM1 antibodies and antigen-binding fragments thereof for reducing T-cell tolerance and for the treatment of cancer and infection.

The invention discloses application of neuron-derived extracellular vesicles carrying ferritin in auxiliary diagnosis of Parkinson's disease, and belongs to the technical field of biomedicine. According to the present invention, the L1 cell adhesion molecule antibody and the ferritin heavy chain antibody are subjected to fluorescence labeling, such that the specific ferritin-carrying neuron-derived extracellular vesicle can be effectively identified in the flow cytometry, and the concentration of the ferritin-carrying neuron-derived extracellular vesicle in the plasma is analyzed so as to determine the concentration of the ferritin-carrying neuron-derived extracellular vesicle, compared with the prior art, the kit provided by the invention has the advantages that PD patients, MSA patients and healthy people can be accurately distinguished, an efficient PD diagnosis biomarker is provided, the capabilities of early PD diagnosis and MSA and PD identification are greatly improved, and the problems of complexity and low sensitivity faced by a traditional diagnosis method can be effectively solved.

Advanced solid tumors remain largely incurable due to the emergence of tumor subclones. These tumor subclones, called metastatic stem cells (MetSCs), are capable of self-renewal, slow cell cycle, tumor relapse, and therapy resistance. The cell adhesion molecule L1CAM has been identified as a key target specifically on MetSCs. The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to L1CAM, and methods of using such antibodies or antigen-binding fragments. The presently disclosed subject matter further provides immunoconjugates comprising anti-L1CAM antibodies or antigen-binding fragments thereof, and methods of using such immunoconjugates.

An in vitro method of preparing a population of hypoimmune mammalian stem cells includes providing a population of isolated mammalian stem cells, wherein the isolated mammalian stem cells express a cell adhesion molecule; and modifying the expression of the cell adhesion molecule in the population of isolated mammalian stem cells to decrease or knockout expression of the cell adhesion molecule and provide the population of hypoimmune mammalian cells. The population of isolated mammalian stem cells can be pluripotent stem cells, or embryonic stem cells, and can be human or non-human stem cells.

This invention discloses a mitochondrial uncoupling agent prodrug with endothelial cell targeting, its preparation method, and its application, relating to the field of biomedical technology. The prodrug is covalently coupled to a vascular cell adhesion molecule-1 targeting polypeptide (amino acid sequence FAKELMEEFEKW), a reactive oxygen species-sensitive thioacetate linker, and the mitochondrial uncoupling agent OPC-163493. This invention utilizes the active enrichment effect of the targeting polypeptide on inflamed pulmonary vascular endothelial cells, overcoming the off-target defects of non-specific distribution in existing small molecule drugs; simultaneously, it utilizes the specific cleavage characteristics of the thioacetate linker in a microenvironment rich in reactive oxygen species to achieve precise in-situ drug release. This prodrug can effectively reduce mitochondrial reactive oxygen species generation, inhibit endothelial cell apoptosis, significantly reduce pulmonary vascular permeability, and alleviate pulmonary edema, possessing significant clinical application value in the preparation of drugs for treating acute lung injury or acute respiratory distress syndrome.

This disclosure provides novel heavy chain-only antibodies, bispecific antibodies, multispecific antibodies, and fusion proteins thereof that bind to Nectin Cell Adhesion Molecule 4 (Nectin-4), related antibody-drug conjugates, related nucleic acids, related cells, related kits, related compositions, and related methods or uses.

The present disclosure is directed to methods for preventing or treating helminth (e.g., filarial) diseases in animals. The methods are accomplished by administering to the animal a therapeutically effective amount of an inhibitor of UDP-glucoronosyl transferase (UGT) or immunoglobulin I-set domain containing protein (Igl-DCP, also known as BMA-Lad-2). The inhibitors include those known to inhibit glucuronyltransferase enzyme activity as well as cell adhesion molecule inhibitors and antibodies specific for Igl-DCP and / or UGT.

A pharmaceutical composition comprising a compound that targets and / or binds to a binding pocket at interface between the D1 and D2 domains of an intracellular portion or fragment of the receptor protein tyrosine phosphatase (RPTP) IIb cell adhesion molecules (e.g., PTPμ) and that is capable of inhibiting RPTP mediated adhesion of cells and / or cancer cell growth and / or sphere formation.

Provided are stabilized formulations of the human carcinoembryonic antigen-related cell adhesion molecule 5 (hCEACAM5)-targeted antibody-drug conjugate huMAb2-3-SPDB-DM4, as well as methods for making and using same.

The application discloses a kind of miRNA-21-5p-rich exosomes and its preparation method and application.The preparation method includes the following steps: culturing mesenchymal stem cells in culture medium containing promoting agent, collecting supernatant, and obtaining miRNA-21-5p-rich exosomes by separation;The promoting agent includes at least one of vascular cell adhesion molecule-1, tumor necrosis factor alpha and interleukin-6.The method can obtain miRNA-21-5p-rich exosomes;The exosome has a therapeutic effect on diabetic foot ulcers, and the therapeutic effect is significantly better than that of exosomes prepared by traditional methods.

The invention discloses a human umbilical cord mesenchymal stem cell three-dimensional aggregate as well as a preparation method and application thereof. The human umbilical cord mesenchymal stem cell aggregate is obtained by adding fusion proteins hE-cadhein-Fc and hN-cadhein-Fc into human umbilical cord mesenchymal stem cells and co-culturing the fusion proteins hE-cadhein-Fc and hN-cadhein-Fc into the human umbilical cord mesenchymal stem cells, the hE-cadherin-Fc is a fusion protein composed of a human intercellular adhesion molecule E-cadherin and an Fc domain of immunoglobulin G, and the hN-cadherin-Fc is a fusion protein composed of an extracellular structural domain of a human intercellular adhesion molecule N-cadherin and an Fc domain of immunoglobulin G. The three-dimensional culture technology of the mesenchymal stem cells can better simulate the in-vivo growth microenvironment of the cells. The invention provides a preparation method for promoting the formation of the three-dimensional culture mesenchymal stem cell aggregate and exerting better biology through cadherin matrix energization. According to the method, the biological characteristics of the mesenchymal stem cells can be optimized, and a remarkable treatment effect is achieved in the aspect of treatment of diabetic nephropathy.